The American College of Cardiology, along with the American Heart Association and the Heart Failure Society of America, released an updated guideline for the management of heart failure.

The guideline update extends the prior guideline update released May 20, 2016 addressing new pharmacological therapy for heart failure. This guideline update includes revision to the sections on biomarkers, including recommendations for the prevention, diagnosis, and prevention or added risk stratification of heart failure; updates on heart failure with preserved ejection fraction; new data on important comorbidities including sleep apnea, anemia and hypertension; and new insights regarding the prevention of heart failure.

“For clinical practice guidelines to be truly useful, new evidence that changes clinical practice should be rapidly incorporated in the guidelines and disseminated to the practice community. These updates were deemed necessary as new evidence in all of the areas addressed, derived from clinical trials, has emerged since the 2013 Heart Failure Guidelines and now merits inclusion,” said Clyde W. Yancy, MD, MSc, MACC, FAHA, FHFSA, chair of the writing group for the document.